{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:13:25Z","timestamp":1790129605398,"version":"4.0.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":86,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.curtheres.2022.100669","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T01:59:08Z","timestamp":1649210348000},"page":"100669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review"],"prefix":"10.1016","volume":"96","author":[{"given":"Silvia","family":"Joseph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffi A.","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8874-0289","authenticated-orcid":false,"given":"Jacob","family":"Peedicayil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2022.100669_bib0001","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/nau.22609","article-title":"Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013","volume":"33","author":"Drake","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.curtheres.2022.100669_bib0002","series-title":"Overactive bladder. In: Campbell's Urology","first-page":"1947","author":"Drake","year":"2012"},{"key":"10.1016\/j.curtheres.2022.100669_bib0003","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0004","series-title":"Campbell- Walsh Urology","first-page":"1786","article-title":"Physiology and pharmacology of the bladder and urethra","author":"Yoshimura","year":"2012"},{"key":"10.1016\/j.curtheres.2022.100669_bib0005","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3892\/etm.2021.10879","article-title":"Overactive bladder: A review and update","volume":"22","author":"Scarneciu","year":"2021","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.curtheres.2022.100669_bib0006","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13181-012-0234-2","article-title":"Writing an effective review article","volume":"8","author":"Murphy","year":"2012","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0007","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2008.03.109","article-title":"Lower urinary tract symptoms revisited: A broader clinical perspective","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0008","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1152\/physrev.00038.2003","article-title":"Urinary bladder contraction and relaxation: Physiology and pathophysiology","volume":"84","author":"Andersson","year":"2004","journal-title":"Physiol Rev"},{"issue":"Suppl 5A","key":"10.1016\/j.curtheres.2022.100669_bib0009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0090-4295(02)01786-7","article-title":"Pharmacologic perspective on the physiology of the lower urinary tract","volume":"60","author":"Andersson","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.curtheres.2022.100669_bib0010","doi-asserted-by":"crossref","first-page":"F257","DOI":"10.1152\/ajprenal.00048.2020","article-title":"Urinary bladder smooth muscle ion channels: Expression, function, and regulation in health and disease","volume":"319","author":"Malysz","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0011","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1515\/jbcpp-2017-0071","article-title":"Calcium sensitization mechanisms in detrusor smooth muscles","volume":"29","author":"Anjum","year":"2018","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0012","doi-asserted-by":"crossref","first-page":"F333","DOI":"10.1152\/ajprenal.00207.2009","article-title":"Activation of the nitric oxide-cGMP pathway reduces phasic contractions in neonatal rat bladder strips via protein kinase G","volume":"297","author":"Artim","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"issue":"Suppl 3","key":"10.1016\/j.curtheres.2022.100669_bib0013","first-page":"S113","article-title":"New targets for overactive bladder \u2013 ICI-RS 2109","volume":"39","author":"Fry","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.curtheres.2022.100669_bib0014","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000447205","article-title":"Overactive bladder syndrome: Evaluation and management","volume":"11","author":"Leron","year":"2018","journal-title":"Curr Urol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0015","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: On the way to tailored treatment","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0016","series-title":"The Pharmacological Basis of Therapeutics","first-page":"149","article-title":"Muscarinic receptor agonists and antagonists","author":"Brown","year":"2017"},{"key":"10.1016\/j.curtheres.2022.100669_bib0017","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1590\/s1677-5538.ibju.2021.99.12","article-title":"Current pharmacotherapy of overactive bladder","volume":"47","author":"Kreydin","year":"2021","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0018","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.26607.1","article-title":"Recent advances in managing overactive bladder","volume":"9","author":"Araklitis","year":"2020","journal-title":"F1000Res"},{"key":"10.1016\/j.curtheres.2022.100669_bib0019","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11934-020-01003-z","article-title":"Are beta 3 adrenergic agonists now the preferred pharmacological management of overactive bladder?","volume":"21","author":"Fogaing","year":"2020","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.curtheres.2022.100669_bib0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1464-410X.2007.06575.x","article-title":"Botulinum toxin A in the overactive bladder: Current status and future directions","volume":"99","author":"Dmochowski","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.curtheres.2022.100669_bib0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000083259","article-title":"Botulinum toxin: Mechanisms of action","volume":"53","author":"Dressler","year":"2005","journal-title":"Eur Neurol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0022","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","article-title":"Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)","volume":"111","author":"Mohee","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.curtheres.2022.100669_bib0023","doi-asserted-by":"crossref","first-page":"e13870","DOI":"10.1111\/ijcp.13870","article-title":"Which drugs are best for overactive bladder? From patients\u2019 expectations to physicians\u2019 decisions","volume":"75","author":"Milsom","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.curtheres.2022.100669_bib0024","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/luts.12304","article-title":"Current management of refractory overactive bladder","volume":"12","author":"Chen","year":"2020","journal-title":"Lower Urinary Tract Symptoms"},{"key":"10.1016\/j.curtheres.2022.100669_bib0025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1474-8673.2009.00447.x","article-title":"Inhibitory effect of anticholinergics on the contraction of isolated caprine urinary bladder detrusor muscle","volume":"30","author":"George","year":"2010","journal-title":"Auton Autacoid Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0026","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ijcp.12540","article-title":"The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; Randomised, double-blind, placebo-controlled phase 2 study","volume":"69","author":"Song","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.curtheres.2022.100669_bib0027","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1517\/13543784.2014.925877","article-title":"Phase II drugs that target cholinergic receptors for the treatment of overactive bladder","volume":"23","author":"Zacche","year":"2014","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.curtheres.2022.100669_bib0028","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/jpet.107.125757","article-title":"GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog","volume":"323","author":"Hicks","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.curtheres.2022.100669_bib0029","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2012.05.053","article-title":"A multicenter, double-blind, randomized, placebo-controlled trial of the \u03b23agonist solabegron for overactive bladder","volume":"62","author":"Ohlstein","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/jpet.112.191783","article-title":"Effects of ritobegron (KUC-7483), a novel selective \u03b23-adrenoceptor agonist, on bladder function in cynomolgus monkey","volume":"342","author":"Maruyama","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.curtheres.2022.100669_bib0031","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00210-012-0755-x","article-title":"Bladder selectivity of the novel \u03b23-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat","volume":"385","author":"Maruyama","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0032","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1476-5381.1991.tb12233.x","article-title":"Comparison of the effects of several potassium-channel openers on rat bladder and rat portal vein in vitro","volume":"102","author":"Edwards","year":"1991","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0033","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000139000","article-title":"Comparison of the in vitro effects of K+ channel modulators on detrusor and portal vein strips from guinea pigs","volume":"45","author":"Zografos","year":"1992","journal-title":"Pharmacology"},{"key":"10.1016\/j.curtheres.2022.100669_bib0034","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0014-2999(94)00685-Z","article-title":"The inhibitory mechanisms of nicorandil in isolated rat urinary bladder and femoral artery","volume":"273","author":"Zhou","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0035","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1358\/mf.2008.30.5.1186078","article-title":"Inhibitory effect of nicorandil on the contraction of isolated human urinary bladder detrusor muscle","volume":"30","author":"Faruqui","year":"2008","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0036","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.urology.2006.03.039","article-title":"Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: Potential therapeutic targets for overactive bladder","volume":"68","author":"Darblade","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.curtheres.2022.100669_bib0037","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1472-8206.2007.00558.x","article-title":"Inhibitory effects of different ATP-sensitive potassium channel openers on electrically generated and carbachol-induced contractions of porcine and human detrusor muscle","volume":"22","author":"Badawi","year":"2008","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0038","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.aju.2011.12.009","article-title":"Inhibitory effects of the ATP-sensitive potassium channel openers cromakalim, pinacidil and minoxidil on the carbachol-responsive curve in porcine detrusor muscle","volume":"10","author":"Badawi","year":"2012","journal-title":"Arab J Urol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0039","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.eururo.2006.01.037","article-title":"Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: A randomized, double-blind, placebo-controlled study (ZD0947IL\/0004)","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0040","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bjp.0704499","article-title":"Spontaneous phasic activity of the pig urinary bladder smooth muscle: Characteristics and sensitivity to potassium channel modulators","volume":"135","author":"Buckner","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0041","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.bjp.0706034","article-title":"Effects of NS1608, a BK(Ca) channel agonist, on the contractility of guinea-pig urinary bladder in vitro","volume":"144","author":"Mora","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0042","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00228-006-0100-8","article-title":"Inhibitory effects of L- and T- type calcium antagonists on contractions of human detrusor muscle","volume":"62","author":"Badawi","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0043","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1476-5381.2011.01543.x","article-title":"Prostaglandin E2 induces spontaneous rhythmic activity in mouse urinary bladder independently of efferent nerves","volume":"165","author":"Kobayter","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0044","unstructured":"Maria SA. To study the effect of cilnidipine on the contraction of isolated caprine detrusor muscle. Thesis submitted to the Tamil Nadu Dr MGR Medical University, Chennai, India, in partial fulfilment for the MD degree in pharmacology, 2021."},{"key":"10.1016\/j.curtheres.2022.100669_bib0045","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1152\/ajpregu.00363.2012","article-title":"SK channel-selective opening by SKA-31 induces hyperpolarization and decreases contractility in human urinary bladder smooth muscle","volume":"304","author":"Soder","year":"2013","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0046","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/bph.12049","article-title":"NS309 decreases rat detrusor smooth muscle membrane potential and phasic contractions by activating SK3 channels","volume":"168","author":"Parajuli","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0047","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/13543784.2019.1654994","article-title":"Agents in early development for treatment of bladder dysfunction \u2013 Promise of drugs acting at TRP channels?","volume":"28","author":"Andersson","year":"2019","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.curtheres.2022.100669_bib0048","doi-asserted-by":"crossref","first-page":"C467","DOI":"10.1152\/ajpcell.00169.2012","article-title":"Novel role for the transient potential receptor melastatin 4 channel in guinea pig detrusor smooth muscle physiology","volume":"304","author":"Smith","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0049","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00424-016-1863-0","article-title":"Functional coupling of TRPV4 channels and BK channels in regulating spontaneous contractions of the guinea pig urinary bladder","volume":"468","author":"Isogai","year":"2016","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.curtheres.2022.100669_bib0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1124\/jpet.119.263616","article-title":"KPR-5714, a novel transient receptor potential melastatin 8 antagonist, improves overactive bladder via inhibition of bladder afferent hyperactivity in rats","volume":"373","author":"Nakanishi","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.curtheres.2022.100669_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.692719","article-title":"TRP channel agonists activate different afferent neuromodulatory mechanisms in guinea pig urinary bladder","volume":"12","author":"Daugherty","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0052","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1520-6777(1996)15:1<59::AID-NAU6>3.0.CO;2-E","article-title":"Effects of various phosphodiesterase - inhibitors, forskolin, and sodium ntroprusside on porcine detrusor smooth muscle tonic responses to muscarigenic stimulation and cyclic nucleotide levels in vitro","volume":"15","author":"Truss","year":"1996","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.curtheres.2022.100669_bib0053","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0090-4295(01)01471-6","article-title":"Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle","volume":"59","author":"Qiu","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.curtheres.2022.100669_bib0054","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1046\/j.1464-410X.2002.02795.x","article-title":"Influence of nitric oxide signalling pathways on pre-contracted human detrusor smooth muscle in vitro","volume":"89","author":"Moon","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.curtheres.2022.100669_bib0055","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1474-8673.2005.00337.x","article-title":"Neuronal nitric oxide synthase activity in rat urinary bladder detrusor: Participation in M3 and M4 receptor function","volume":"25","author":"Orman","year":"2005","journal-title":"Auton Autacoid Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0056","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejphar.2010.04.008","article-title":"Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle","volume":"637","author":"B\u00e1u","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0057","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1476-5381.2010.00748.x","article-title":"Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle","volume":"160","author":"Oger","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0058","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.pharep.2019.03.004","article-title":"Sildenafil corrects the increased contractility of rat detrusor muscle induced by alprostadil in vitro","volume":"71","author":"Bassiouni","year":"2019","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.curtheres.2022.100669_bib0059","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/bph.14669","article-title":"Influence of sildenafil on the purinergic components of nerve-mediated and urothelial ATP release from the bladder of normal and spinal cord injured mice","volume":"176","author":"Chakrabarty","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0060","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4103\/ijabmr.IJABMR_339_18","article-title":"Avanafil inhibits the contractility of the isolated caprine detrusor muscle","volume":"9","author":"Dhruva","year":"2019","journal-title":"Int J Appl Basic Mes Res"},{"key":"10.1016\/j.curtheres.2022.100669_bib0061","first-page":"1559","article-title":"Efficacy of tadalafil once daily versus fesoterodine in the treatment of overactive bladder in older patients","volume":"19","author":"Dell'atti","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.curtheres.2022.100669_bib0062","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.urology.2016.11.008","article-title":"Efficacy of daily low-dose tadalafil for treating overactive bladder: Results of a randomized, double-blind, placebo-controlled trial","volume":"100","author":"Chen","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.curtheres.2022.100669_bib0063","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/luts.12283","article-title":"Efficacy of tadalafil therapy and changes in oxidative stress levels in male patients with lower urinary tract symptoms and overactive bladder","volume":"12","author":"Matsuo","year":"2020","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.curtheres.2022.100669_bib0064","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s11255-017-1671-2","article-title":"Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast","volume":"49","author":"Ding","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0065","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/sj.bjp.0704241","article-title":"contractions on calcium sensitization and calcium entry through LOE-908-sensitive channels","volume":"134","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0066","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bcp.2007.06.004","article-title":"Comparitive pharmacological analysis of Rho- kinase inhibitors and identification of molecular components of Ca2+ sensitization in the rat lower urinary tract","volume":"74","author":"Teixeira","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0067","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1442-2042.2009.02397.x","article-title":"Effects of fasudil, a Rho-kinase inhibitor, on contraction of pig bladder tissues with or without urothelium","volume":"16","author":"Tatsumiya","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0068","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2008.09.045","article-title":"Stimulated calcium entry and constitutive RhoA kinase activity cause stretch-induced detrusor contraction","volume":"599","author":"Poley","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2011.11.047","article-title":"Functional role of muscarinic receptor subtypes in calcium sensitization and their contribution to rho-kinase and protein kinase C pathways in contraction of human detrusor smooth muscle","volume":"79","author":"Shahab","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.curtheres.2022.100669_bib0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1474-8673.2012.00470.x","article-title":"Tramadol inhibits the contractility of isolated caprine detrusor muscle","volume":"32","author":"Kumar","year":"2012","journal-title":"Auton Autacoid Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0071","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/nau.21214","article-title":"Effect of the anticonvulsant medications pregabalin and lamotrigine on urodynamic parameters in an animal model of neurogenic detrusor overactivity","volume":"31","author":"Loutochin","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.curtheres.2022.100669_bib0072","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/nau.20928","article-title":"Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder","volume":"30","author":"Marencak","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.curtheres.2022.100669_bib0073","doi-asserted-by":"crossref","first-page":"7650","DOI":"10.1038\/ncomms8650","article-title":"Pirt reduces bladder overactivity by inhibiting purinergic receptor P2X3","volume":"6","author":"Gao","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.curtheres.2022.100669_bib0074","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/jpp\/rgab072","article-title":"The inhibitory effect of trimetazidine on detrusor contractility: A potential repositioning of trimetazidine for the treatment of overactive bladder","volume":"74","author":"Engin","year":"2022","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.curtheres.2022.100669_bib0075","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/nau.24272","volume":"39","author":"Rovner","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.curtheres.2022.100669_bib0076","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2147\/TCRM.S291798","article-title":"Gene therapy for overactive bladder: A review of BK-channel \u03b1- subunit gene transfer","volume":"17","author":"Andersson","year":"2021","journal-title":"Ther Clin Risk Manag"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X2200008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X2200008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:58:55Z","timestamp":1757897935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X2200008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":76,"alternative-id":["S0011393X2200008X"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2022.100669","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2022.100669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100669"}}